Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Donahue, Renee N ^a   Lepone, Lauren M ^a   Grenga, Italia ^a   Jochems, Caroline ^a   Fantini, Massimo ^a   Madan, Ravi A ^a   Heery, Christopher R ^a   Gulley, James L ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ADCC; Anti PD L1; Antibody dependent cell mediated cytotoxicity; Avelumab; Checkpoint inhibitor; Immune subsets; Immunotherapy; Peripheral immunome

Indexed keywords

AVELUMAB; CD27 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; IMMUNOGLOBULIN G1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ADRENAL CORTEX CARCINOMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CHORDOMA; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; DRUG DOSE ESCALATION; FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPING TECHNIQUE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NORMAL HUMAN; OPEN STUDY; OVARY CARCINOMA; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SPINDLE CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CYTOLOGY; IMMUNOLOGY; MONONUCLEAR CELL; NEOPLASM; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CD40 LIGAND; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7;

EID: 85013393906     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0220-y     Document Type: Article

References (35)

1. Callahan MK, et al. Targeting T cell co-receptors for cancer therapy. Immunity. 2016;44:1069-78.
2. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235-47.
3. Boyerinas B, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148-57.
4. Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7:33498-5110.
5. Khanna S, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993-200.
6. Vandeveer AJ, et al. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res. 2016;4:452-62.
7. Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunol. 2016;5:e83.
8. Cheol Chung H, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. American Society of Clinical Oncology 2016 Annual Meeting. J Clin Oncol. 2016;34 (suppl; abstr 4009).
9. Disis ML, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. American Society of Clinical Oncology 2016 Annual Meeting. J Clin Oncol. 2016; 34 (suppl; abstr 5533).
10. Hassan R, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression [abstract]. American Socity of Clinical Oncology 2016 Annual Meeting. J Clin Oncol. 2016; 34 (suppl) 8503.
11. Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. J Clin Oncol. 2015;33(suppl):abstr 3044.
12. Rajan A, et al. Safety and clinical activity of anti-programed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs). ASCO Annual Meeting J Clin Oncol. 2016;34 (suppl; abstr e20106).
13. Verschraegen CF, et al. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: safety, clinical activity, and PD-L1 expression. American Society of Clinical Oncology 2016 Annual Meeting. J Clin Oncol. 2016;34 (suppl; abstr 9036).
14. Kaufman HL, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-850.
15. Lepone LM, et al. Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types. J Circ Biomark. 2016;5. doi: 10.05772/623220.
16. Madan RA, et al. Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. Oncologist. 2013;18:821-2.
17. Madan RA, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:501-8.
18. Ravetch JV, et al. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989;170:481-97.
19. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol. 2002;2:8.
20. Wang W, et al. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.
21. Huang J, et al. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol. 2013;190:6250-8.
22. Huang J, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012;120:3030-8.
23. Taylor RJ, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2009;58:997-1006.
24. Conlon KC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33:74-82.
25. Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 2014;10:1689-701.
26. Chen S, et al. A targeted IL-15 fusion protein with potent anti-tumor activity. Cancer Biol Ther. 2015;16:1415-21.
27. Dubois S, et al. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol. 2008;180:2099-106.
28. Lehrnbecher T, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood. 1999;94:4220-32.
29. Farsaci B, et al. Analyses of pretherapy peripheral immunoscore and response to vaccine therapy. Cancer Immunol Res. 2016;4:755-65.
30. Czystowska M, et al. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res. 2013;19:889-99.
31. Jordan KR, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62:1711-22.
32. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4.
33. Campbell DE, et al. Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes. Clin Vaccine Immunol. 2009;16:1648-53.
34. Binyamin L, et al. Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy. J Immunol. 2008;180:6392-401.
35. Voskens CJ, et al. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res. 2010;29:134.